Clinical trials: Labor Stage, First
Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07881211
- Testing
- BG-T0050
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Bronchopulmonary Dysplasia
Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants.
- Trial name
- NCT01897987
- Testing
- Pneumostem®, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Medipost Co Ltd.
Non-small Cell Lung Cancer
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs".
- Trial name
- NCT05800015
- Testing
- fianlimab, cemiplimab, Pemetrexed
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 160 people
- Sponsor
- Regeneron Pharmaceuticals
HIV -1 Infection
Study of GS-0415 and How It Works in People With HIV
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and…
- Trial name
- NCT07719491
- Testing
- GS-0415
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Gilead Sciences
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Advanced Non-Small Cell Lung Cancer
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs".
- Trial name
- NCT05557591
- Testing
- BNT116, Cemiplimab
- Where
- 52 sites in United States, Georgia and 5 more
- Volunteers
- 51 people
- Sponsor
- Regeneron Pharmaceuticals
Diffuse Large B-Cell Lymphoma, B-cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0920 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07887646
- Testing
- BG-T0920
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Parkinson's Disease
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT06916507
- Where
- 19 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1.
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT06758401
- Testing
- Sigvotatug Vedotin, Pembrolizumab
- Where
- 389 sites in United States, Argentina and 29 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Advanced Solid Tumors
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy.
- Trial name
- COMBINE-EGFR-1 (NCT04626635)
- Testing
- REGN7075, Cemiplimab, Platinum-based doublet chemotherapy
- Where
- 54 sites in United States, France and 5 more
- Volunteers
- 548 people
- Sponsor
- Regeneron Pharmaceuticals
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).
- Trial name
- Opti-GAIN (NCT07392255)
- Testing
- CTx001
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Cancers With HER2 Expression
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor Receptor 2) and cannot be cured by…
- Trial name
- NCT04147819
- Testing
- BAY2701439
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Bayer
Healthy
A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants
The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants.
- Trial name
- NCT05481333
- Testing
- REGN7999
- Where
- Belgium
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hepatocellular Carcinoma
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein…
- Trial name
- BANTAM-01 (NCT06764316)
- Testing
- BAY 3547926, BAY 3547922, BAY 3713391
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 148 people
- Sponsor
- Bayer